ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis

This study is currently recruiting participants.
Verified by Bayside Health, September 2005

Sponsors and Collaborators: Bayside Health
National Health and Medical Research Council, Australia
Monash University
Cystic Fibrosis Australia
Information provided by: Bayside Health
ClinicalTrials.gov Identifier: NCT00163852
  Purpose

Adult cystic fibrosis (CF) patients admitted with an acute infection complicated by acid-base disturbance and decreased ventilation will be studied.

They will receive salt replacement to correct the acid-base disturbance and possibly their ventilation.

Assessment of symptoms (questionnaire), acid-base and electrolyte status (blood and urine tests) ventilation (overnight oxygen and carbon dioxide monitoring non-invasively) and sleep-wake pattern (actigraphy) will be carried out.

Study hypothesis: Acute volume and electrolyte replacement corrects hypochloremic hypovolemic metabolic alkalosis and compensatory hypoventilation/ hypercapnia in acute exacerbations of cystic fibrosis.


Condition Intervention Phase
Cystic Fibrosis
Drug: Normal saline IV, salt tablets
Phase II
Phase III

Genetics Home Reference related topics:   cystic fibrosis   

MedlinePlus related topics:   Cystic Fibrosis    Dietary Sodium   

ChemIDplus related topics:   Sodium chloride   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:   Salt Replacement for Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis

Further study details as provided by Bayside Health:

Primary Outcome Measures:
  • Primary outcome measures: (Day1, D4, D10)
  • •PaCO2 (performed at same time of day as admission ABG’s)
  • •Acid-base status (Stinebaugh and Austin, ABG’s)
  • •Serum chloride
  • •Overnight oximetry (% night SpO2<90%) and PtcCO2 (rise in CO2 overnight)

Secondary Outcome Measures:
  • Secondary outcome measures: (Day1, D4, D10)
  • •Serum albumin, sodium
  • •Body mass index (BMI)
  • •Spirometry (D1, D10)
  • •Headache scale
  • •Epworth sleepiness scale
  • •Wrist actigraphy (circadian rhythm and daytime activity level)(D1-10)
  • •Urinary chloride, potassium, sodium, pH, osmolality
  • •Baseline ABG’s as stable outpatient (within 3 months, pre or post admission)

Estimated Enrollment:   40
Study Start Date:   February 2004
Estimated Study Completion Date:   February 2006

Detailed Description:

Background: Hypochloremic hypovolemic metabolic alkalosis contributes to hypercapnia in acute exacerbations of cystic fibrosis. Treatment of the metabolic alkalosis with volume and sodium chloride (NaCl) replacement could reduce hypoventilation and hypercapnia, thereby improving symptoms, sleep patterns and daytime activity level. This would avoid unnecessary treatment with non-invasive ventilation.

Hypothesis: Volume and NaCl replacement corrects hypochloremic hypovolemic metabolic alkalosis and compensatory hypoventilation/ hypercapnia in acute exacerbations of cystic fibrosis and results in symptomatic improvement.

Entry criteria:

  • Adult cystic fibrosis patient
  • Admission with acute exacerbation
  • PaCO2 > 45 mmHg
  • Primary metabolic alkalosis (acid-base diagram of Stinebaugh and Austin)
  • Serum chloride (Cl) ≤ 98 mmol/L
  • Serum albumin (alb) > 25 mmol/L

Intervention:

  • Normal saline intravenously day(D)1,2,3. (Replace greater of Cl deficiency or acute weight loss, with 2/3 on D1 and remainder D2, D3)
  • NaCl tablets 3 tds D4 to 10 (calculated to replace 7 mmol NaCl loss in 60 kg subject)

Random allocation to either:

  1. Intervention + standard care (including standard dietary advice) D1-10
  2. Standard care alone (including standard dietary advice) D1-10

Primary outcome measures: (D1, D4, D10)

  • PaCO2 (performed at same time of day as admission ABG’s)
  • Acid-base status (Stinebaugh and Austin, ABG’s)
  • Serum chloride
  • Overnight oximetry (% night SpO2<90%) and PtcCO2 (rise in CO2 overnight)

Secondary outcome measures: (D1, D4, D10)

  • Serum albumin, sodium
  • Body mass index (BMI)
  • Spirometry (D1, D10)
  • Headache scale
  • Epworth sleepiness scale
  • Wrist actigraphy (circadian rhythm and daytime activity level)(D1-10)
  • Urinary chloride, potassium, sodium, pH, osmolality
  • Baseline ABG’s as stable outpatient (within 3 months, pre or post admission)
  Eligibility
Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria:

  • Adult cystic fibrosis patient
  • Admission with acute exacerbation (criteria- fall in FEV1 > 10% from best in last 12/12, change in sputum volume and colour, new pulmonary infiltrate)
  • PaCO2 > 45 mmHg on admission
  • Primary metabolic alkalosis (acid-base diagram of Stinebaugh and Austin)
  • Serum chloride (Cl) ≤ 98 mmol/L
  • Serum albumin (alb) ≤ 25 mmol/L

Exclusion Criteria:

Concurrent diuretic therapy Concurrent glucocorticoid therapy

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00163852

Contacts
Contact: Alan C Young, MBBS, FRACP     613 9276 2000 ext pager 4576     alan.young@med.monash.edu.au    
Contact: Matthew T Naughton, MBBS, FRACP     613 9276 2000 ext 3770     m.naughton@alfred.org.au    

Locations
Australia, Victoria
The Alfred     Recruiting
      Melbourne, Victoria, Australia, 3181
      Contact: Alan C Young, MBBS     613 9276 2000 ext pager 4576     alan.young@med.monash.edu.au    
      Sub-Investigator: Alan C Young, MBBS            

Sponsors and Collaborators
Bayside Health
National Health and Medical Research Council, Australia
Monash University
Cystic Fibrosis Australia

Investigators
Principal Investigator:     Matthew T Naughton, MBBS, MD     The Alfred    
  More Information

Study ID Numbers:   14/04
First Received:   September 12, 2005
Last Updated:   September 12, 2005
ClinicalTrials.gov Identifier:   NCT00163852
Health Authority:   Australia: Therapeutic Goods Administration

Keywords provided by Bayside Health:
Cystic fibrosis  
Metabolic alkalosis  
Hypercapnia  
Salt replacement  

Study placed in the following topic categories:
Metabolic Diseases
Hypercapnia
Fibrosis
Digestive System Diseases
Cystic Fibrosis
Respiratory Tract Diseases
Genetic Diseases, Inborn
Lung Diseases
Pancreatic Diseases
Infant, Newborn, Diseases
Metabolic disorder
Alkalosis
Cystic fibrosis

Additional relevant MeSH terms:
Pathologic Processes
Acid-Base Imbalance

ClinicalTrials.gov processed this record on September 05, 2008




Links to all studies - primarily for crawlers